Search Results
University College Cork, Medicine, Cork, Ireland
Search for other papers by Conleth G Murphy in
Google Scholar
PubMed
Joan and Sanford I Weill Medical College of Cornell University, Medicine, New York, New York, USA
Search for other papers by Maura N Dickler in
Google Scholar
PubMed
progression-free survival (PFS) was seen between the three arms. Subsequent prospective–retrospective analysis of ESR1 mutation status in archival plasma circulating tumor DNA (ctDNA) indicated improved outcomes with fulvestrant compared with exemestane
International Cancer Prevention Institute, Epalinges, Switzerland
Search for other papers by Berna C Özdemir in
Google Scholar
PubMed
Search for other papers by George Sflomos in
Google Scholar
PubMed
ISREC – Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
Search for other papers by Cathrin Brisken in
Google Scholar
PubMed
prognostic significance ( Shao et al . 2015 ). During the last years, liquid biopsies referring to the analysis of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) have been developed as surrogate markers to inform on tumor
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Isabel Coutinho in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Tanya K Day in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Luke A Selth in
Google Scholar
PubMed
(CTCs) and cell-free circulating tumor DNA (ctDNA) from patients with CRPC ( Antonarakis et al . 2014 , Carreira et al . 2014 , Azad et al . 2015 ). Although AR amplification is frequent in CRPC and an important driver of therapy resistance, AR
Search for other papers by Jennifer R Eads in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Tim Asmis in
Google Scholar
PubMed
Search for other papers by Andrew M Bellizzi in
Google Scholar
PubMed
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Michael Frumovitz in
Google Scholar
PubMed
Search for other papers by Joshua Meyer in
Google Scholar
PubMed
Search for other papers by Erik Mittra in
Google Scholar
PubMed
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Search for other papers by Eric Nakakura in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Heloisa P Soares in
Google Scholar
PubMed
Search for other papers by Brian Untch in
Google Scholar
PubMed
Search for other papers by Namrata Vijayvergia in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
( Subbiah et al. 2022 ). Of note, the earlier NEN sequencing efforts have been conducted in tumor tissue specimens and work on circulating tumor specimens is limited and investigational. In the CIRCAN-NEC pilot study, circulating tumor DNA (ctDNA) was
Search for other papers by S M Sadowski in
Google Scholar
PubMed
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by C R C Pieterman in
Google Scholar
PubMed
Search for other papers by N D Perrier in
Google Scholar
PubMed
Search for other papers by F Triponez in
Google Scholar
PubMed
Search for other papers by G D Valk in
Google Scholar
PubMed
worse prognosis; however, this was determined in a cohort of metastatic NETs of all sites, not solely pancreatic NETs ( Khan et al. 2011 , 2013 ). Given the low mutational burden in pNET, use of circulating tumor DNA (ctDNA) as prognostic biomarker
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Neil Portman in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Sarah Alexandrou in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Emma Carson in
Google Scholar
PubMed
Search for other papers by Shudong Wang in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Elgene Lim in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by C Elizabeth Caldon in
Google Scholar
PubMed
mutations. In the PALOMA-3 trial, fulvestrant plus palbociclib improved PFS in patients with ESR1 mutant and ESR1 WT circulating tumour DNA (ctDNA), indicating that CDK4/6 inhibitors are effective irrespective of ESR1 mutation status ( Fribbens et al
Search for other papers by Suzan Stelloo in
Google Scholar
PubMed
Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Andries M Bergman in
Google Scholar
PubMed
Department of Biomedical Engineering, Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands
Search for other papers by Wilbert Zwart in
Google Scholar
PubMed
interesting approach, applicable for patients with large burden of ctDNA, could be identification of nucleosome footprints in ctDNA. Analysis of two plasma samples taken 12 months apart, during which the prostate adenocarcinoma transdifferentiated to a
Search for other papers by Elgene Lim in
Google Scholar
PubMed
Search for other papers by Gerard Tarulli in
Google Scholar
PubMed
Search for other papers by Neil Portman in
Google Scholar
PubMed
Search for other papers by Theresa E Hickey in
Google Scholar
PubMed
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Search for other papers by Carlo Palmieri in
Google Scholar
PubMed
status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2− advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 tria